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Abstract
Background: MicroRNAs (miRNAs) are short, non-coding RNAs that regulate gene expression mainly through
translational repression of target mRNA molecules. More than 2700 human miRNAs have been identified and some
are known to be associated with disease phenotypes and to display tissue-specific patterns of expression.
Methods: We used high-throughput small RNA sequencing to discover novel miRNAs in 93 human post-mortem
prefrontal cortex samples from individuals with Huntington’s disease (n = 28) or Parkinson’s disease (n = 29) and
controls without neurological impairment (n = 36). A custom miRNA identification analysis pipeline was built, which
utilizes miRDeep* miRNA identification and result filtering based on false positive rate estimates.
Results: Ninety-nine novel miRNA candidates with a false positive rate of less than 5 % were identified. Thirty-four
of the candidate miRNAs show sequence similarity with known mature miRNA sequences and may be novel
members of known miRNA families, while the remaining 65 may constitute previously undiscovered families of
miRNAs. Nineteen of the 99 candidate miRNAs were replicated using independent, publicly-available human brain
RNA-sequencing samples, and seven were experimentally validated using qPCR.
Conclusions: We have used small RNA sequencing to identify 99 putative novel miRNAs that are present in human
brain samples.
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Background
MicroRNAs (miRNAs) are a class of small, noncoding
regulatory RNAs. In their mature form, miRNAs are
single-stranded, 19–23 nucleotides in length, most often
generated from hairpin precursors transcribed from inter-
genic, intronic, or exonic regions of the genome. Mature
miRNAs act as post-transcriptional regulators of gene ex-
pression through sequence-specific targeted binding of
mRNA. The most common mechanism of regulation by
miRNAs is translational repression of targeted mRNA. A
single miRNA may target multiple mRNAs and a single
mRNA may be targeted by multiple miRNAs [1, 2].
The importance of miRNA regulation of mRNAs and
its effect on organism phenotype is not yet fully under-
stood, but it is clear that it is a widespread phenomenon
[3]. miRNAs are found in plants and animals and func-
tion in a variety of biological processes including cell
growth, proliferation and apoptosis [4]. It has been esti-
mated that more than half of all mammalian protein-
coding mRNAs experience some degree of miRNA regu-
lation [5]. Considering this, it is unsurprising that the
deregulation of miRNAs has been associated with many
diseases, including neurodegenerative diseases such as
Huntington’s disease and Parkinson’s disease [6, 7].
miRNAs can be species-specific and many display
tissue-specific patterns of expression [3, 8]. More than
2700 known human mature miRNAs are documented in
miRBase v20 [9], a number that has increased rapidly in
the past, due largely to the increasing availability and qual-
ity of next-generation sequencing yielding larger numbers
of RNA-seq data sets from a wider variety of tissue types
[10]. Nonetheless, few human brain samples have been
mined for the discovery of novel miRNAs, relative to more
available tissue types. This yields the possibility that there
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are brain-specific and possibly human-specific miRNAs
that have yet to be discovered.
The goal of this study was to identify novel, potentially
brain-specific miRNA species using miRNA sequencing
from 93 human prefrontal cortex tissue samples, compris-
ing persons with Huntington’s disease (HD) or Parkinson’s
disease (PD) and neurologically healthy controls. Novel
miRNAs were identified using the miRDeep* procedure
[11] and final results were annotated for sequence similar-
ity to known miRNAs, proximity to genes, and potential
expression differences between disease and control sam-
ples. A portion of the putative novel miRNAs were experi-
mentally validated from a set of independent samples.
Methods
Sample Information is provided in Additional file 1 and
summarized in Table 1. The pipeline methods are depicted
as a flowchart in Fig. 1.
Sample preparation and sequencing
Frozen brain tissue from the prefrontal cortex Brodmann
Area 9 (BA9) was available from three brain banks: the
National Brain and Tissue Resource for Parkinson’s Disease
and Related Disorders at Banner Sun Health Research
Institute, Sun City, Arizona, the Harvard Brain Tissue Re-
source Center McLean Hospital, Belmont, Massachusetts,
and the Human Brain and Spinal Fluid Resource Center
VA, West Los Angeles Healthcare Center, California.
Isolation and purification of total RNA was done using
QIAzol Lysis Reagent and miRNeasy MinElute Cleanup
columns, respectively. RNA quality was assessed either by
RNA Quality number from Agilent’s BioAnalyzer 2100 and
RNA 6000 Nano Kits, or by RNA Quality Number from
Agilent 2200 TapeStation and Agilent DNA ScreenTape
assay. Sequencing libraries were constructed using 1 μg of
RNA per sample and Illumina’s TruSeq Small RNA Sample
Prep Kit with the manufacturer’s protocol. Illumina’s
HiSeq 2000 system was used for 1×51 nucleotides,
single-end sequencing, conducted at Tufts University
(http://tucf-genomics.tufts.edu/) or Michigan State se-
quencing core facility (http://rtsf.natsci.msu.edu/genomics/).
Batch 1 and batch 2 used eight samples per lane with equal
numbers of HD and control samples per lane. In batch 3,
all samples were given unique bar-codes and distributed
across all lanes, with the number of lanes and samples allo-
cated to reach the target read depth of 16,000,000 reads per
sample. Additional file 2 contains per sample raw read
depth and quality control information.
Sequencing analysis
Adaptor sequences were trimmed from the reads using
cutadapt v. 1.2.1 [12], discarding reads with length less than
15 nucleotides and longer than 27 nucleotides. Sequencing
reads whose length was greater than 80 % bases with Phred
quality score less than 20 were removed using the fas-
tq_quality_filter command line function from FASTX-
Toolkit (version 0.0.14) [13]. Alignment of miRNA sequen-
cing reads to the human reference genome build hg19 was
performed using Bowtie v. 1.1.1 [14], allowing no mis-
matches (v = 0) and up to 200 instances of multi-mapping
(m = 200). More stringent read length filtering was done by
miRDeep* before identification of novel miRNAs, discard-
ing reads with length less than 18 nucleotides and greater
than 23 nucleotides, miRDeep* default parameters. Differ-
ential expression analyses used the less stringent length fil-
tered reads. Additional file 2 contains per sample quality
control information including the number of reads used in
miRNA discovery and in differential expression analyses.
Identification of novel miRNAs
The identification of miRNAs was performed using the
tool miRDeep* v. 35 [11]. miRDeep* determines the lo-
cation of putative miRNAs based on aligned small RNA
sequencing reads, and scores each prediction with a
measure of the likelihood that the miRDeep* result is a
true miRNA. The miRDeep* score takes into account ar-
tifacts of miRNA precursor processing by Dicer and
Drosha, including the positions, lengths and relative fre-
quencies of reads that align to the three precursor prod-
ucts (mature miRNA, star sequence and hairpin loop),
and the presence of a short 3’ overhang on the mature
sequence. In addition, the score is increased by larger
read depth, the evolutionary conservation of the 5’ end
of the mature sequence, and the stability of the predicted
miRNA hairpin secondary structure.
The alignment files from all 93 samples were
concatenated, divided by chromosome into 25 separ-
ate alignment files, and sorted. miRDeep* was run
on each chromosome separately. The 99 final miRDeep*
results were those that were both novel and passed the
miRDeep* score threshold, which was determined using
estimations of the false positive rate (FPR) and true posi-
tive rate (TPR). To make these estimations, the miRDeep*
predictions for each chromosome were combined and di-
vided into three categories based on hairpin mapping lo-
cation: 1) known exons and small RNAs other than










Age at death [years]
60.1 (40–86) 77.6 (64–95) 68.6 (40–97)
Mean (range) PMIa [hours] 16.7 (4–37) 11.1 (1–31) 14.4 (2–28)
Mean (range) RINb 7.3 (6.0–9.2) 7.3 (5.5–8.5) 7.7 (6.3–8.7)
% male 93 % 100 % 92 %
aPostmortem interval
bRNA Integrity Number
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miRNAs, 2) known hairpin miRNAs, and 3) results that
map to the remainder of the genome. This categorization
was done using bedtools v2.22.1 [15] with annotation files
for exons and small RNAs from gencode v19 [16] and
miRNAs from miRBase v20 [9]. Instances where the exon
and miRNA annotations overlapped were excluded, be-
cause we could not be certain whether there is a true
miRNA within an exon or one of the annotations is
inaccurate.
For every integer score value between the minimum
and maximum scores of miRDeep* miRNA predictions,
the FPR and TPR were estimated using the categoriza-
tions of feature overlap described above. The FPR was
calculated as the number of miRDeep* predictions with
score above the threshold overlapping exon or small
RNA annotations, divided by the total number of miR-
Deep* predictions overlapping exon or small RNA anno-
tations. Similarly, the TPR was calculated as the number
of miRDeep* predictions overlapping known miRNAs
with score above the threshold, divided by the total
number of miRDeep* predictions overlapping known
miRNAs. We chose the integer score threshold that
yielded a FPR nearest 0.05. In order to get a more pre-
cise value than the integer score, we repeated this pro-
cedure with non-integer thresholds +/- 1 at 0.01
increments of the integer threshold.
Sequence similarity with known miRNAs
The miRDeep* novel mature sequences were aligned to ma-
ture miRNA sequences in miRBase v20 using the SSEARCH
alignment algorithm from the FASTA program package
[17], filtering results for e-value < 0.05 and nucleotide over-
lap > = 15. For the novel miRNA and miRBase miRNA pairs
with high-quality alignments of mature sequences, the hair-
pin sequences were aligned using SSEARCH as well. The
quality of alignment on the miRNA seed sequence
Fig. 1 Flowchart depiction of the novel miRNA discovery pipeline.
This flowchart shows our novel miRNA discovery pipeline beginning
with the small RNA sequencing of tissue samples, quality control
(cutadapt v. 1.2.1, FASTX-Toolkit v. 0.0.14) and alignment of sequencing
reads in fastq file format, and preparation of alignment (bam) files for
miRDeep*. The miRNA predictions made by miRDeep* were classified as
false positives (gencode v19 exons/sRNA), true positives (miRBase
v20 miRNA), or potential novel miRNAs, which were filtered
further. In the flowchart, the yellow box represents miRDeep* results
that occurred on both exon and miRNA annotations, which were
excluded from the analysis. The false positives were used to determine a
miRDeep* score threshold with a false positive rate close to 0.05, which
was used to filter the miRDeep* results that are neither false positives
nor true positives. The result of this filtering step was a final set of
putative novel miRNAs. This set was annotated with differential
expression analysis (HD/C and PD/C), alignment (SSEARCH) of mature
miRNA sequences to known human mature miRNA sequences in
miRBase v20, and proximity to human genes
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(positions 2–7 from the 5’ end of the mature sequence) was
recorded with the number of mismatches or gaps within
each seed sequence. Pairwise alignments of miRDeep* novel
sequences were performed in the same way as alignments to
miRBase entries.
Differential expression analysis of Huntington’s disease/
control and Parkinson’s disease/control
Differential expression analysis was performed with a set
of miRNAs including the novel putative miRNAs identi-
fied in this study together with known human mature
miRNAs from miRBase v20. The results of the novel
miRNAs are presented here, and the differential expres-
sion of known miRNAs within these data has been pre-
viously characterized and published for both HD/control
[7] and PD/control [18]. Small RNA sequencing reads
were counted using htseq-count from the Python pack-
age htseq v. 0.6.1 [19]. miRNAs with 0 read counts in
more than half of the samples were disregarded by the dif-
ferential expression analysis. A variance-stabilizing trans-
formation (VST) was performed using DESeq2 v. 1.6.3
[20], and batch correction was performed using ComBat
[21] from the Bioconductor package sva v. 3.12.0 [22] with
default options and with all samples. The differential ex-
pression analysis was done using linear models imple-
mented using the Bionconductor package LIMMA v.
3.22.7 [23], adjusting for age of death and with FDR-
adjusted p-values. Bioconductor v. 3.0 and R v. 3.1.1 were
used in these analyses. The HD/C (Huntington’s disease
and control) analysis was conducted with 36 control and
28 HD brains, and the PD/C (Parkinson’s disease and con-
trol) analysis with the same 36 control brains and 29 PD
brains. The differential expression analysis is limited by
the data’s origination from separate studies, introducing
potential biases on gene expression levels, though miti-
gated however possible.
Replication of novel microRNAs
Our putative novel miRNAs were replicated using two pub-
licly available small RNA sequencing data sets, obtained
from the Gene Expression Omnibus. Santa-Maria et al.
(GSE63501) contains 16 human post-mortem Brodmann
Area 9 small RNA sequencing samples from individuals
with Alzheimer’s disease, tangle-predominant dementia and
normal neuropathology. Hebert et al. (GSE46131) contains
20 human post-mortem superior and mid-temporal neo-
cortex grey matter small RNA sequencing samples from in-
dividuals with Alzheimer’s disease, dementia with Lewy
bodies, hippocampal sclerosis of aging, frontotemporal
lobar dementia (FTLD) and normal neuropathology. All 36
samples from these studies were concatenated for our repli-
cation analysis. miRNA results from the original and repli-
cation analyses were compared by genomic location using
the bedtools v2.22.1 intersect function.
Experimental validation of novel microRNAs
Seven putative novel miRNAs were selected for orthog-
onal validation using the Exiqon miRCURY LNA Univer-
sal RT microRNA PCR system. RNA for these analyses
was purified and extracted, as described above, from a set
of twelve independent brains. The putative novel miRNAs
selected for qRT-PCR analysis represent a wide range of
mean expression values (5-5708 mean reads). We priori-
tized novel miRNAs with significant differential expres-
sion. Exiqon custom microRNA LNA PCR primers were
designed using the miRNA primer design algorithm avail-
able online at exiqon.com. Total RNA was DNased using
the TURBO DNA-free Kit following the manufacturer’s
instructions (Ambion/Thermo Fisher Scientific). cDNA
was generated from 100 ng of RNA using the Universal
cDNA synthesis kit II and RNA Spike-in kit following the
manufacturer’s instructions (Exiqon). For each sample, a
cDNA reaction was performed omitting reverse tran-
scriptase (-RT reaction). qPCR was performed using the
ExiLENT SYBR Green Master mix kit following the man-
ufacturer’s instructions (Exiqon) and using either a 1:80 or
1:20 dilution of the cDNA reaction as template. Two + RT
reactions and one -RT reaction were performed for each
sample and primer set. qPCR was done on a StepOnePlus
Real-Time PCR System (ABI/Thermo Fisher Scientific)
using the cycling and analysis parameters recommended
by Exiqon (Instruction manual v6.1).
Results
miRDeep* analysis of sequence alignment data from 93
pooled prefrontal cortex samples revealed 8891 miRNAs.
Out of these, 3641 remained after filtering for known miR-
NAs from miRBase v20, other small RNAs and exons. The
remaining miRNA results were filtered by the miRDeep*
score, a measure of the likelihood that the miRDeep* result
is a true miRNA, where higher scores indicate higher confi-
dence of a miRNA result. In our miRDeep* results, score
ranged from -9.98 to as high as 11 million, with a median
of -0.85.
The score value to be used as a threshold was deter-
mined by estimating false positive rate (FPR) and true
positive rate (TPR) using the scores of the 4273 results
overlapping with known exons and small RNAs (false pos-
itives) and of the 783 results overlapping with known miR-
NAs (true positives), excluding the 194 results overlapping
both annotations. The performance of this method was
evaluated with a receiver operating characteristic (ROC)
curve, a plot of the FPR vs. TPR as the threshold is varied,
shown in Additional file 3. The area under the curve
(AUC) of the ROC curve, used as a metric of the quality
of the classifier, is 0.82 with this method. A score of 86.13
had an estimated FPR of 0.05 and TPR of 0.45, and was
used as the score threshold.
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Figure 2 displays a Venn diagram showing the number
of score-filtered miRDeep* results which overlap the set
of hairpin miRNAs within miRBase v20 (both sets were
filtered for exons and other small RNAs). After applying
the score threshold of 86.13 to the 3641 novel miRDeep*
results, a final list of 99 putative novel miRNAs was
identified. Sixty-five of the 99 potential miRNAs were in-
tronic, an additional 13 were within 1000 base pairs of
at least one gene, and the remaining 21 were further
than 1000 base pairs from any annotated gene from gen-
code v19. This information is represented as a pie chart
in Fig. 3. The 99 results are present within a varying
number of the samples, ranging from 2 to all 93, with a
mean of 69.4 samples. Sixteen results are present in
fewer than half of the samples, while ten are expressed
ubiquitously and with a large mean read depth. The dis-
tribution of the miRNA results’ mean counts by number
of samples present is described in Additional file 4. Raw
counts of the novel mature miRNA regions are available
in Additional file 5, and summary information on the 99
miRDeep* results is shown in Additional file 6. This in-
cludes genomic location, sequence, predicted hairpin
secondary structure, miRDeep* score, nearby genes, and
summary of differential expression analyses and align-
ments to miRBase v20 entries.
Nineteen of the 99 putative novel miRNAs were repli-
cated using two independent human brain small RNA se-
quencing data sets obtained from the Gene Expression
Omnibus (GEO access numbers GSE63501 and GSE46131)
[24–26]. Using these publicly available GEO samples
(N = 36), the replication analysis resulted in 30 puta-
tive miRNAs. Matching by overlap of genomic location,
19 of 30 were seen in our original 99 results. The
remaining 11 were not found in our data. Thirty-three of
the 99 putative novel mature miRNAs were reported in a
recent novel miRNA study by Londin et al. [3]. Eleven of
the 99 putative miRNAs described in this study appear
both in the replication results and in the Londin et al. data
set. Figure 4 displays a Venn diagram that depicts the
overlap of the 99 novel miRNAs, the 30 replication novel
miRNAs and the Londin et al. novel miRNAs data set.
Seven of the 99 putative novel miRNAs plus two
known miRNAs that represent the extremes of the ex-
pected range of expression were chosen for experimental
validation using qRT-PCR (Additional file 7). All 9 were
determined to be expressed in an independent set of 12
brains. Each putative novel miRNA was present in at
least 7 of the 12 brain samples analyzed. Moreover, the
expression levels as determined by qRT-PCR paralleled
the relative expression levels determined by small RNA
sequencing.
Fig. 2 miRDeep* putative miRNAs and miRBase miRNAs. This Venn
diagram depicts the overlap between two sets of hairpin miRNAs.
The first is the set of miRDeep* results after score-filtering (86.13)
and filtering to remove exons and sRNAs, using annotation files from
gencode v19 and matching by genomic locations with the intersect
function from bedtools v2.22.1. This set of 454 miRDeep* results
overlaps the set of miRBase v20 hairpin miRNAs, also filtered for exons
and sRNAs with the same method. As seen in the Venn diagram, the
majority of the score and exon/sRNA filtered miRDeep* results exist
within the miRBase database. The 99 that do not are the final putative
novel miRNAs of this study. (*) The total number of filtered miRBase
hairpin miRNAs is not the sum of the intersection and the remaining
miRBase set because the miRBase and miRDeep* hairpin miRNAs do
not have a one-to-one relationship. Twenty-two of the miRDeep* set
overlap two members of the miRBase set, and eight of the miRBase set
overlap two members of the miRDeep* set. In this Venn diagram we
have displayed that 355 of the 454 filtered miRDeep* hairpin miRNA
predictions overlap at least one filtered miRBase v20 hairpin miRNA,
and 1138 of 1507 filtered miRBase v20 hairpin miRNAs overlap zero
filtered miRDeep* hairpin miRNA predictions
Fig. 3 Genomic locations of the putative novel miRNAs. The
locations of the 99 novel miRNAs relative to human genes are
depicted as a pie chart. It shows the proportion of the 99 novel
miRNAs that are within, near (<= 1000 basepairs), or distant
(>1000 basepairs) from one or more genes from gencode v19.
The 65 novel miRNA results that are within genes are intronic, as
cases of miRDeep* results overlapping gencode v19 exon
annotations were classified as false positives and excluded
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Using the SSEARCH aligner, 34 of the 99 putative
novel mature miRNAs align well (e < 0.05 and nucleotide
overlap > = 15) to at least one known mature miRNA
from miRBase v20. Most of these 34 aligned to 1–4 dis-
tinct miRNAs, but 6 aligned to a large number (18–69)
of sequences within the miRNA gene family hsa-miR-
548. Pairwise alignments of the 99 putative novel mature
miRNAs revealed that 34 align to at least one other re-
sult. Five of the six sequences that aligned to the hsa-
miR-548 family also aligned to each other. Additional file
8 contains information on the alignments to miRBase en-
tries, and Additional file 9 contains information on the
pairwise alignments. Two results, chr22_novelMiR_136
and chr22_novelMiR_137, may be the same miRNA. The
two have the same mature sequence and location, very
similar, large miRDeep* score, but differing hairpin
locations. Though they may be distinct transcripts, one
was excluded from the differential expression analysis to
avoid double-counting the large number of shared reads.
Differential expression analysis of known miRNAs (miR-
Base v20) plus our 99 putative novel miRNAs was com-
pleted using linear models adjusting for age of death. This
analysis showed 4 of the 99 putative miRNAs to be differen-
tially expressed between control (n= 36) and Huntington’s
disease (n = 28) samples, and another 3 to be differentially
expressed between control (n= 36) and Parkinson’s disease
(n= 29) samples at False Discovery Rate of 5 % (See Table 2).
The four HD-associated putative miRNAs have negative
log2 fold-change values (lower average expression within the
disease samples), and of the three PD-associated putative
miRNAs, one has a negative log2 fold-change and two have
positive log2 fold-changes.
The data presented in Table 2 were generated by
LIMMA v. 3.22.7
Discussion
We have discovered 99 putative novel miRNAs, of which
7 have been experimentally validated using qPCR and 19
have been replicated in an independent brain-tissue de-
rived small RNA sequencing data set. Furthermore, 33
of the 99 match novel miRNAs discovered recently by
Londin et al. [3], which utilized 1323 samples from 16
tissue types, including 24 from brain tissue. Eleven puta-
tive novel miRNAs appear in all three result sets (ori-
ginal, replication and Londin sets), four of which were
among the seven experimentally verified. The experi-
mental confirmation of presence within brain samples
and the overlap of our findings with those of past studies
suggests these novel findings are likely valid miRNAs.
There are several possible reasons why 80 of 99 results
were not replicated by the independent data set and 66
of 99 are not seen in the Londin et al. miRNA data set,
including differences of disease status, brain region and
sample size, and the presence of false positives. The in-
dependent data set contains samples from studies of
Alzheimer’s disease and dementia but lack HD or PD
brains, and one of these studies used temporal neocortex
grey matter, while we used prefrontal cortex. The
Fig. 4 Putative novel miRNAs, replication data miRNAs and Londin
et al. miRNAs. This Venn diagram depicts the overlap of three sets of
mature miRNAs: the novel mature miRNAs discovered using the HD
and PD small RNA sequencing data set, the novel mature miRNAs
discovered using the publicly available replication data set, and the
Londin et al. mature miRNAs. The intersection of sets was obtained
using the intersect function from bedtools v2.22.1 with gene transfer
format (gtf) annotations files created by the novel miRNA discovery
pipeline and from the supplemental data set of Londin et al. Though
the sets vary in size, each has unique miRNA entries and overlap with
each other set
Table 2 Differentially expressed novel miRNAs for Huntington’s disease and Parkinson’s disease
Putative novel miRNA Contrast Average log2 expression log2FC p-value FDR-adjusted p-value
chr9_novelMiR_203 HD/C 4.03 −1.58 4.91E-04 2.06E-02
chr11_novelMiR_242 2.65 −0.69 2.84E-04 1.40E-02
chr16_novelMiR_272 2.59 −0.76 1.67E-04 1.11E-02
chr18_novelMiR_75 1.32 −0.66 5.83E-04 2.19E-02
chr6_novelMiR_46 PD/C 2.03 0.55 1.58E-03 2.02E-02
chr8_novelMiR_236 1.78 0.53 5.47E-03 4.46E-02
chr9_novelMiR_225 1.92 −0.62 7.20E-04 1.15E-02
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original data set contains 93 brain samples while the
replication data set contains 36, and although Londin et
al. utilized 1323 small RNA-seq samples, only 24 of
these are from brain tissue. Our 93 brain samples are
likely to have a greater power to detect potential brain-
specific miRNAs, and the Londin et al. data has the
capability to detect tissue-specific miRNAs from 15
additional tissues and greater power to detect tissue-
nonspecific miRNAs.
Thirty-four of the 99 results aligned well to known miR-
NAs. These may be novel members of known miRNA
families. miRNA family classification is based on sequence
(especially seed) similarity, as well as function similarity,
conservation and common descent. While we have shown
sequence similarity that may indicate potential miRNA fa-
milial membership, we cannot definitively determine
membership with these data alone. The 65 novel results
that did not align well to any currently known miRNA
may be novel miRNAs that do not belong to any currently
known family.
miRNAs are known to exhibit tissue-specific patterns
of expression [3, 8] and because these novel miRNAs
have been discovered with pre-frontal cortex samples,
they may be specific to the brain or to the prefrontal
cortex. Tissue-specificity could explain why these miR-
NAs have not been previously discovered, as miRNA
discovery is not typically performed using brain tissue.
However, this may alternatively be explained by our
large sample size and the sequencing depth that our
concatenation method invokes rather than by tissue-
specific expression.
We performed differential expression analysis of the
99 putative novel miRNAs, of which, after adjusting for
multiple comparisons with FDR q-value < 0.05, 3 are sig-
nificantly differentially expressed for PD and 4 are sig-
nificantly differentially expressed for HD. These seven
are not only putative novel miRNAs and potentially spe-
cific to the brain, but are potentially associated with neu-
rodegenerative disease. Five of the seven (including all of
the HD-associated miRNAs) have lower average expres-
sion within the disease samples relative to control sam-
ples. Currently, we cannot know whether these miRNAs
are involved in the pathogenic mechanisms of disease or
are only indirectly associated. Future studies would be
required to understand the role of these seven miRNAs
in PD or HD pathogenicity.
It should be noted that the batching of samples was
done originally for two separate studies, and that differ-
ent brain banks specialize in different diseases (e.g. the
HBTRC is the largest source of Huntington samples).
Consequently, these data by necessity are limited by the
association between brain bank and batch, and brain
bank and disease status. Although we have attempted to
mitigate possible biases by implementing identical
sample preparation protocols for the studies and correc-
tion of batch effects with the Combat batch correction
procedure, these differences may have introduced a bias
on gene expression levels. This limitation should be ap-
preciated for the differential expression analyses.
We have developed a method utilizing miRDeep* to
discover novel miRNAs from concatenated small RNA
sequencing samples. Many existing miRNA discovery
tools use samples individually, while others pool sam-
ples, similar to our approach [27]. The main advantage
to pooling data is that it allows the discovery of lowly
expressed miRNAs that have too few reads to be suc-
cessfully evaluated on a per sample basis [27]. As a con-
sequence of this, the miRNA discovery does not account
for the distribution of miRNAs across samples, so that a
miRNA may be discovered whether it is expressed ubi-
quitously or within a subset of samples. A disadvantage
to our method is that it will not discover the rare cases
of legitimate miRNAs coded within exons, which com-
prise approximately 5 % of currently annotated miRNAs
[3], due to our focus on generating high-confidence
predictions.
Conclusion
We have developed a pipeline that utilizes miRDeep*,
pooled RNA sequencing samples and a score filtering
method to discover novel miRNAs with high confidence.
This pipeline was applied to 93 post-mortem human
prefrontal cortex samples, yielding 99 putative novel
miRNAs. Seven of these putative novel miRNAs were
validated experimentally and 19 were replicated using an
independent post-mortem human brain RNA sequen-
cing data set. A subset of the 99 results may be specific
to the brain or to the prefrontal cortex, and 7 show dif-
ferential expression between HD and control or PD and
control samples. More than a third of the putative
miRNA sequences align well to known miRNAs and
may be novel members of known miRNA families, while
the remaining may be members of novel miRNA
families.
Our discovery and characterization of putative novel
miRNAs may add to the rapidly-growing repository of
known human miRNAs. These results reinforce the possi-
bility that many miRNAs display tissue-specific expression
and will only be discovered once many more tissue types
are characterized for miRNA discovery. In addition, miR-
NAs have been implicated in neurodegenerative diseases,
and seven of the miRNAs that we have discovered may
not only be specific to the brain, but are associated with
neurodegenerative disease in the samples available for the
current study. We know very little about these miRNAs,
and while they may be only peripherally or coincidentally
associated with HD and PD, these results may eventually
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contribute to the understanding of the molecular mecha-
nisms of these diseases.
Additional files
Additional file 1: Provides information on each of the 93 samples used
in this study. This information includes ID, type (Control/HD/PD), PMI
(Post-mortem-interval), age at death, sex, batch, brain bank, and cause of
death. (XLSX 13 kb)
Additional file 2: Contains quality control information including the
average read quality before and after quality and length filtering, the
number of reads used in miRNA discovery and in differential expression
analyses, and the number of reads removed for each length and quality
filtering step. Length filtering used 15 and 27 nucleotides as threshold for
the differential expression analysis and a more strict 18 and 23
nucleotides for the miRDeep* miRNA discovery. The numbers of reads
filtered are included for all four thresholds. (XLSX 22 kb)
Additional file 3: Shows the receiver operating characteristic curve from
the novel miRNA discovery method. (PNG 29 kb)
Additional file 4: A scatter plot depicting for each putative novel miRNA
the number of samples that have at least one read count, vs. the mean
count value of those samples. (PNG 15 kb)
Additional file 5: A 99 × 93 table with raw read counts of the 99
putative novel miRNA results, for each of the 93 samples. (XLSX 45 kb)
Additional file 6: Contains summary information of each of the 99
novel putative miRNAs and the 30 miRNAs results from public data, in
separate tabs. The following information is included in this file: mature
and hairpin sequence loci, miRDeep* score, expression, the number of
good-quality alignments to miRBase entries, the name of the miRBase
entry with the best alignment, the name and distance (basepairs) of any
gene within 1000 basepairs of the novel miRNA, adjusted p-value and
log2 fold-change of the differential expression analyses (C v. HD, C v. PD),
whether the novel miRNA overlaps an entry within the Londin et al.
novel miRNA dataset, which entries of the HD/PD data set and the public
data set results match by location, which novel miRNAs were experimentally
validated, mature and hairpin sequence, and predicted hairpin secondary
structure. (XLSX 35 kb)
Additional file 7: A table containing information on the qRT-PCR
performed with seven novel miRNAs and two known miRNAs. Per
miRNA, this information includes mean CT, range of CT, cDNA dilution, the
number of samples (of 12) with CT < 40, the average read depth, and primer
used. (XLSX 8 kb)
Additional file 8: Contains alignment information from good-quality
mature sequence alignments of the 99 putative novel miRNAs to
miRBase mature sequence entries. (XLSX 46 kb)
Additional file 9: Contains alignment information from good-quality
alignments of pairwise alignments of mature sequences of the 99 putative
novel miRNAs. (XLSX 15 kb)
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